Synairgen plc Synairgen appoints Gareth Walters, Ph.D. as CRO
13 Octubre 2021 - 1:00AM
RNS Non-Regulatory
TIDMSNG
Synairgen plc
13 October 2021
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces the appointment of
Gareth Walters, Ph.D. as Chief Regulatory Officer
Brings more than 30 years of experience in the pharmaceutical
and biotech industries and a deep understanding of global
regulatory strategy and business leadership
Southampton, UK - 13 October 2021: Synairgen plc (LSE: SNG), the
respiratory company developing inhaled interferon beta for the
treatment of severe viral lung infections, today announces the
appointment of Gareth Walters, Ph.D. to the newly-created role of
Chief Regulatory Officer in preparation for SNG001 regulatory
submissions.
Richard Marsden, CEO of Synairgen, commented : "We're delighted
to welcome Gareth to our growing team. His experience and expertise
in global regulatory strategy will be invaluable as we prepare for
SNG001 regulatory submissions."
Dr. Walters brings more than 30 years' expertise of global
regulatory strategy to Synairgen: from preclinical, to marketing
authorisation, through to post-approval and commercialisation.
Before joining Synairgen, Dr. Walters served as Global Regulatory
Affairs Head (Research & Early Development) and Head of
European Regulatory Affairs for Chugai Pharmaceuticals, where he
led strategic and operational regulatory activities in Europe,
Japan and the US. Prior to his time at Chugai, Dr. Walters held
various senior regulatory and executive management and Board roles
at several pharmaceutical and biotech companies, as well as
commercial and clinical positions at Roche. During this time he
played a key role in bringing innovative new medicines to the
market, including in the US and Europe.
Gareth Walters, Ph.D., newly appointed Chief Regulatory Officer
of Synairgen added : "I am thrilled to be joining Synairgen at such
a pivotal moment for the Company. The anticipated conclusion of the
Phase III trial in the coming months for SNG001 is a critical
milestone for the Company in its goal of bringing interferon beta
to hospitalised patients with COVID-19. I look forward to
collaborating closely with the team and driving a global regulatory
programme that helps deliver a therapy to patients that has the
potential to reduce the burden on hospitals and healthcare
systems."
-ENDS-
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
Consilium Strategic Communications (UK Financial Media and
Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted
broad-spectrum antiviral treatment delivered directly into the
lungs. Granted Fast Track status from the US Food and Drug
Administration (FDA) and deemed an Urgent Public Health study by
the UK's National Institute for Health Research (NIHR), Synairgen's
Phase III clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase II trial in
hospitalised COVID-19 patients, SNG001 demonstrated a greater than
twofold chance of recovery to 'no limitation of activities' versus
placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
1 -
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMTBMTMTJBTLB
(END) Dow Jones Newswires
October 13, 2021 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024